RankAlpha logo
Back to Rankings

GILD

Gilead SciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Q2 ex-Veklury growth and the raised full-year sales outlook provide an operating foundation; stronger HIV prevention uptake and successful integration of the wholly owned Arcellx pipeline could improve longer-run earnings quality. The deterministic prior is positive, but this is not yet a confirmed post-Q3-earnings thesis.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · AMC.
What can break
PepStar's HCXT-2001 is in Phase 1, has no established safety or efficacy, and its acquisition remains subject to closing conditions. [#PR-2026-10-22]
Momentum
88
Value
64
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $159.00 · Bull $174.00 · Bear $135.00Analysis 2026-10-23; returns require an exact persisted reference.
Earnings
43 · Non-qualifying
Next 2026-10-29 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-23 • Model: RankAlpha Sentiment Codex
Earnings Setup
As of 2026-10-26 • RankAlpha AI
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $161.32
Why
Momentum88 · Δ7d -8.8
Value64 · Δ7d -0.1
Sentiment57 · Δ7d +11.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Earnings surprise screen
43Non-qualifying2026-10-29 amc
View setup

Gilead has a confirmed October 29 report date, strong recent product-demand themes, and a record of frequent EPS and revenue beats, but available checks did not establish positive current-quarter EPS revisions or a credible revenue-upside signal; the recent tape also lacks a confirmed 1.5x-volume accumulation day and a close-location above 0.75 in the latest session. The evidence does not meet the required pre-earnings setup checks.

Screen as of 2026-10-26. Window 2026-10-26 to 2026-10-30.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · AMC.
  • • Pre-earnings setup: 43 / non-qualifying.
  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • PepStar's HCXT-2001 is in Phase 1, has no established safety or efficacy, and its acquisition remains subject to closing conditions. [#PR-2026-10-22]
  • • Q2 GAAP and non-GAAP losses reflected large acquired-IPR&D and tax charges; additional PepStar spending is expected to reduce Q4 EPS if the deal closes. [#SEC-8K-2026-08-04] [#PR-2026-10-22]
  • • Acquisition-related charges, lower cash after deal spending, and uncertain clinical returns can offset commercial growth.

Catalyst clock

2026-10-29 · AMC

Third-quarter results are scheduled for October 29, not October 22

Lead driver: Value · See fundamentals
Momentum
88
8% active weight
Current posture
7d trendSoftening
Δ7d
-8.8
Δ21d
-1.7
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.1
Sentiment
57
45% active weight
Current posture
7d trendImproving
Δ7d
+11.3
Δ21d
-3.9
Why this grade

Composite grade A. Momentum 87.7 / Value 63.7 / Sentiment 56.6

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-23. Scenario method

B+
Bull case
25%
Probability
Target price
$174.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Most likely
B
Base case
55%
Probability
Target price
$159.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$193.48B
Beta
0.37
Shares Out
1.24B
P/E (TTM)
18.4
P/S (TTM)
5.05
P/FCF (TTM)
28.33
Rev YoY
+10.7%
EPS YoY
-640.7%
Gross Margin
+79.7%
Op Margin
+39.1%
Net Debt
$15.93B
Current Ratio
1.27
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data